Moving and improving for Omicron

Published: 31-Mar-2010
Manufacturing Finance

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Omicron Research Limited, the UK distributor for CAMAG and Distek Inc., is excited to announce that it will be based in new premises from April 2010.

Located in Hungerford, Berkshire, the modern, fully redecorated building will house the office, warehouse and workshop departments of our scientific equipment distribution and support business. For the first time, Omicron’s complete operation will be housed under one roof, providing a more responsive and streamlined service to customers.

A substantial investment has been made into the refurbishment of the new premises and the upgrade of technology, ensuring continuation of the high level of customer service for which Omicron is renowned. With immediate access to the M4, the new location offers staff and clientele a more convenient and professional environment in which to do business.

To coincide with the move the company hase enhanced its website by adding two new functionalities. An extensive parts catalogue is now available on-line, complemented by a new quotation request facility, providing a fast, easy to use service for customers. We invite you to visit and explore our website, www.omicron-uk.com, where you will find information on an extensive range of dissolution, chromatography, spectroscopy, OPLC and capillary electrophoresis products.
See more

You may also like

Manufacturing

HPTLC – a thoroughly modern method

Read more
High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  5. Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

HPTLC – a thoroughly modern method

High Performance Thin Layer Chromatography (HPTLC) is firmly established as a fast and effective analytical tool, yet in many laboratories traditional TLC is still the norm.
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Finance

UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show

Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Britain's biotech potential (part I): world-class science, second-class support?

The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Subscribe now